WGS GeneDx Holdings Corp. - Class A Common Stock

NAS · US · Technology · Diagnostics & Research · genedx.com

74.01USD+1.27%Mkt Cap: 2.18B $P/E: —Today

GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and inf…

Industry Peers

Diagnostics & Research

Screen all

TMO

Thermo Fisher Scientific Inc Common Stock

$242.11BUSDP/E 35.5

DHR

Danaher Corporation Common Stock

$150.48BUSDP/E 38.2

NTRA

Natera, Inc. - Common Stock

Agilent Technologies, Inc. Common Stock

$47.30BUSDP/E 33.1

IQV

IQVIA Holdings, Inc. Common Stock

$42.50BUSDP/E 32.2

WAT

Waters Corporation Common Stock

$41.75BUSDP/E 107.4

ILMN

Illumina, Inc. - Common Stock

$41.23BUSDP/E 50.8

IDXX

IDEXX Laboratories, Inc. - Common Stock

$40.89BUSDP/E 36.4

MTD

Mettler-Toledo International, Inc. Common Stock

$29.78BUSDP/E 34.0

DGX

Quest Diagnostics Incorporated Common Stock

$25.75BUSDP/E 25.0

Labcorp Holdings Inc. Common Stock

$25.02BUSDP/E 25.5

Guardant Health, Inc. - Common Stock

$23.86BUSD

RVTY

Revvity, Inc. Common Stock

$16.91BUSDP/E 72.5

MEDP

Medpace Holdings, Inc. - Common Stock

$16.73BUSDP/E 35.2

ERF

Eurofins Scientific SE

$13.92BUSDP/E 26.0

CRL

Charles River Laboratories International, Inc. Common Stock

$13.85BUSD

ICLR

ICON plc - Ordinary Shares

Qiagen N.V. Common Shares

$9.24BUSDP/E 22.7

Key Statistics

Company

Market Cap2.18B USD

Enterprise Value2.21B USD

Revenue (TTM)454.43M USD

Gross Profit298.17M USD

Net Income (TTM)-21.02M USD

Revenue/Share15.55 USD

Last Price74.01 USD

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees1.3K

CountryUS

SectorTechnology

IndustryDiagnostics & Research

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)60.98

PEG—

EV/EBITDA-65.72

EV/Revenue4.87

P/S4.80

P/B8.92

EPS (TTM)-3.63

EPS (Forward)1.20

52W Range

32.2130% of range170.87

52W High170.87 USD

52W Low32.21 USD

Profitability

Gross Margin69.74%

Oper. Margin-15.21%

EBITDA Margin-7.41%

Profit Margin-4.92%

ROE-6.82%

ROA-4.01%

Growth

Revenue Growth11.40%

Earnings Growth—

Cash Flow & Leverage

Operating CF33.28M USD

CapEx (TTM)19.02M USD

FCF Margin-10.45%

FCF Yield-2.18%

Net Debt34.85M USD

Net Debt/EBITDA-1.03

Balance Sheet

Debt/Equity0.37

Current Ratio3.30

Quick Ratio2.90

Book Value/Sh8.19 USD

Cash/Share4.45 USD

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 USD

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Splits

Last Split1:33

Split DateMay 4, 2023

Analyst Consensus

Rating1.1 (Strong Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)93.50 USD

Upside (mean)+26.3%

Target Range83.00 USD – 103.00 USD

83.00+26.3% to mean103.00

# Analysts8

Ownership

Shares Out.29.82M

Float20.44M

Insiders7.71%

Institutions107.57%

Short Interest

Short Ratio11.9d

Short % Float37.77%

Short % Out.19.73%

Shares Short5.88M

Short (prev mo.)6.29M

Technical

SMA 5081.26 (-8.9%)

SMA 20078.38 (-5.6%)

Beta2.01

S&P 52W Chg14.58%

Avg Vol (30d)662.38K

Avg Vol (10d)966.02K

Technical Indicators

RSI (14)40.5

MACD-0.9157

MACD Signal1.9184

MACD Hist.-2.8342

BB Upper99.88 USD

BB Middle85.15 USD

BB Lower70.41 USD

BB Width34.61%

ATR (14)6.292 USD

Vol Ratio (20d)0.83x